¡Ya estamos en ! Descubre más

Fulgent Genetics

FLGT

Capitalización de mercado USD 545 M

19.81 USD

-1.53

7.17%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

19.92

+0.11

0.56%

1 día

-7.17%

5 días

-8.88%

1 mes

-8.41%

3 meses

-3.6%

6 meses

22.81%

En lo que va del año

-22.59%

1 año

-13.11%

5 años

-75.42%

10 años

143.37%

Acerca de: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

Empleados: 1,315

Atención médica Diagnósticos e investigación

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 16.7%

Neutral 50%

Negativo 33.3%

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q.

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Zacks Investment Research

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics Q2 Earnings Call Highlights

Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.

Fulgent Genetics Q2 Earnings Call Highlights

Zacks Investment Research

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Reports Second Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue of $85.4 million GAAP loss of $29.5 million, or $(1.05) per share Non-GAAP loss of $16.2 million, or $(0.58) per share Adjusted EBITDA loss of $17.1 million Non.

Fulgent Reports Second Quarter 2026 Financial Results

Fulgent Genetics: Strong Moves By Management Keep Me Bullish

Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight management's conviction in FLGT's intrinsic value. FLGT trades below tangible book value, with net assets per share estimated at $24.09–$29, offering a margin of safety.

Fulgent Genetics: Strong Moves By Management Keep Me Bullish

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer que.

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

Fulgent Presents Updated FID-007 Data at ASCO 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID.

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™